Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746044 | 1.00 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL6746055 | 1.00 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| Hydrochloric Acid SCHEMBL6746169 | 0.98 | MAOB (0.54) | MAOBADORA3ARKDM4ECYP19A1 | |
| Hydrochloric Acid SCHEMBL6746174 | 0.98 | MAOB (0.54) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL23662356 | 0.83 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL6746035 | 0.83 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL30997908 | 0.83 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL6828123 | 0.83 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL8596185 | 0.80 | MAOB (0.53) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL11377847 | 0.80 | SIGMAR1 (0.66) | MAOBADORA3ARKDM4ECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812353-B2 | INTERMEDIATES FOR CENTRAL NERVOUS SYSTEM MEDICATIONS; PRIMARY AMINE FUNCTIONALITY | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-11-02 | — | — | US | claimed |
| US-20040092579-A1 | Central nervous system diosrders; catalytic hydrogenation | MERCK GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| EP-1317438-A1 | CHROMANONE DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-06-11 | — | — | EP | claimed |
| WO-2002020507-A1 | CHROMANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-03-14 | — | — | WO | claimed |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4329765-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022231927-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-6812353-B2 | INTERMEDIATES FOR CENTRAL NERVOUS SYSTEM MEDICATIONS; PRIMARY AMINE FUNCTIONALITY | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20040092579-A1 | Central nervous system diosrders; catalytic hydrogenation | MERCK GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1317438-A1 | CHROMANONE DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020507-A1 | CHROMANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092579-A1 | Central nervous system diosrders; catalytic hydrogenation | CBR3, CBR1, HCRTR1 | MAOB 221/4885ADORA3 403/4885AR 199/4885 |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | MAOB 3715/4885ADORA3 3903/4885AR 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.